Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced the acceptance of three abstracts for presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, TX, from Nov. 6-10, 2024. The presentations will highlight Lyell's pipeline of clinical product candidates and anti-exhaustion technology for cell therapies targeting solid tumors and hematologic malignancies.
Key presentations include:
- Translational data from the LYL797 Phase 1 clinical trial, demonstrating solid tumor infiltration and cell killing by reprogrammed ROR1 CAR T cells
- Multiomic profiling of LYL119, a reprogrammed ROR1 CAR T product with reduced exhaustion and enhanced memory characteristics
- Utilization of Stim-R™ Technology to reduce irradiated feeder cells in tumor infiltrating lymphocyte culture process
These presentations will provide insights into Lyell's progress in developing innovative cell therapies for cancer treatment.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) ha annunciato l'accettazione di tre abstract per la presentazione al 39° Congresso Annuale della Society for Immunotherapy of Cancer (SITC) che si terrà a Houston, TX, dal 6 al 10 novembre 2024. Le presentazioni metteranno in evidenza il portafoglio di candidati clinici di Lyell e la tecnologia anti-esaurimento per terapie cellulari rivolte a tumori solidi e neoplasie ematologiche.
Le presentazioni chiave includono:
- Dati traslazionali dal trial clinico di Fase 1 LYL797, che dimostrano l'infiltrazione nei tumori solidi e l'uccisione cellulare da parte delle cellule CAR T ROR1 riprogrammate
- Profilazione multiomica di LYL119, un prodotto CAR T ROR1 riprogrammato con ridotto esaurimento e caratteristiche di memoria potenziate
- Utilizzo della Stim-R™ Technology per ridurre le cellule nutrizionali irradiate nel processo di coltivazione dei linfociti tumore-infiltranti
Queste presentazioni forniranno approfondimenti sul progresso di Lyell nello sviluppo di terapie cellulari innovative per il trattamento del cancro.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) anunció la aceptación de tres resúmenes para su presentación en el 39° Congreso Anual de la Sociedad para la Inmunoterapia del Cáncer (SITC) en Houston, TX, del 6 al 10 de noviembre de 2024. Las presentaciones resaltarán la cartera de candidatos clínicos de Lyell y la tecnología anti-agotamiento para terapias celulares dirigidas a tumores sólidos y malignidades hematológicas.
Las presentaciones clave incluyen:
- Datos transnacionales del ensayo clínico Fase 1 LYL797, que demuestran la infiltración en tumores sólidos y la destrucción celular por parte de las células CAR T ROR1 reprogramadas
- Perfilado multiómico de LYL119, un producto CAR T ROR1 reprogramado con agotamiento reducido y características de memoria mejoradas
- Utilización de la Stim-R™ Technology para reducir las células alimentadoras irradiadas en el proceso de cultivo de linfocitos infiltrados en tumores
Estas presentaciones proporcionarán información sobre el progreso de Lyell en el desarrollo de terapias celulares innovadoras para el tratamiento del cáncer.
Lyell Immunopharma, Inc. (Nasdaq: LYEL)는 2024년 11월 6일부터 10일까지 텍사스 휴스턴에서 개최되는 제39회 암 면역 요법 학회(SITC)에서 발표할 세 가지 초록의 수락을 발표했습니다. 이 발표들은 고형 종양과 혈액암을 대상으로 하는 세포 치료를 위한 Lyell의 임상 제품 후보군과 세포 피로 방지 기술을 강조할 것입니다.
주요 발표 내용은 다음과 같습니다:
- LYL797 임상 시험 1상의 전이 데이터로, 재프로그램된 ROR1 CAR T 세포에 의한 고형 종양 침윤 및 세포 사멸을 보여줍니다.
- 재프로그램된 ROR1 CAR T 제품인 LYL119의 다중 오믹스 프로파일링으로, 피로가 감소하고 기억 특성이 향상되었습니다.
- 종양 침윤 림프구 배양 과정에서 방사선으로 처리한 공급 세포를 줄이기 위한 Stim-R™ 기술의 활용
이 발표들은 암 치료를 위한 혁신적인 세포 치료 개발에 대한 Lyell의 진전을 파악하는 데 도움을 줄 것입니다.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) a annoncé l'acceptation de trois résumés pour présentation lors du 39ème Congrès Annuel de la Société pour l'Immunothérapie du Cancer (SITC) à Houston, TX, du 6 au 10 novembre 2024. Les présentations mettront en avant le portefeuille de candidats thérapeutiques cliniques de Lyell et la technologie anti-épuisement pour les thérapies cellulaires ciblant les tumeurs solides et les cancers hématologiques.
Les présentations clés comprennent :
- Données translationnelles de l', démontrant l'infiltration des tumeurs solides et l'élimination des cellules par les cellules CAR T ROR1 reprogrammées
- Profilage multiomique de LYL119, un produit CAR T ROR1 reprogrammé avec un épuisement réduit et des caractéristiques de mémoire améliorées
- Utilisation de la Stim-R™ Technology pour réduire les cellules nourricières irradiées dans le processus de culture des lymphocytes infiltrant les tumeurs
Ces présentations fourniront des perspectives sur les progrès de Lyell dans le développement de thérapies cellulaires innovantes pour le traitement du cancer.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) gab die Annahme von drei Abstracts zur Präsentation auf dem 39. Jahresmeeting der Gesellschaft für Immuntherapie von Krebs (SITC) in Houston, TX, vom 6. bis 10. November 2024 bekannt. Die Präsentationen werden Lyells Pipeline klinischer Produktkandidaten und die Anti-Ermüdungstechnologie für Zelltherapien, die auf solide Tumoren und hämatologische Malignitäten abzielen, hervorheben.
Wichtige Präsentationen umfassen:
- Translationaldaten aus der LYL797 Phase 1 klinischen Studie, die die Tumorinfiltration und Zellzerstörung durch reprogrammierte ROR1 CAR T-Zellen demonstrieren
- Multiomisches Profiling von LYL119, einem reprogrammierten ROR1 CAR T-Produkt mit reduziertem Erschöpfungsgrad und verbesserten Gedächtniseigenschaften
- Nutzung der Stim-R™ Technology zur Reduzierung von bestrahlten Futterzellen im Kulturprozess von tumorinfiltrierenden Lymphozyten
Diese Präsentationen werden Einblicke in Lyells Fortschritte bei der Entwicklung innovativer Zelltherapien zur Krebsbehandlung geben.
- Acceptance of three abstracts for presentation at a major scientific conference (SITC)
- First presentation of translational data from LYL797 Phase 1 clinical trial showing tumor infiltration and cell killing
- Development of LYL119 with reduced exhaustion and enhanced memory characteristics
- Advancement of Stim-R™ Technology for improved tumor infiltrating lymphocyte culture process
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, announced today that three abstracts highlighting its pipeline of clinical product candidates and anti-exhaustion technology have been accepted for presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place in Houston, TX, Nov. 6-10, 2024.
The three presentations highlight anti-exhaustion technology and product candidates being advanced in Lyell’s pipeline of cell therapies for solid tumors and hematologic malignancies, including the first presentation at a scientific conference of translational data from the LYL797 Phase 1 clinical trial demonstrating solid tumor infiltration and cell killing by reprogrammed ROR1 CAR T cells.
Details of the poster presentations are below:
LYL797 ROR1 CAR T-cell Translational Data Demonstrated T-cell Reprogramming Limited Exhaustion, Maintained Stemness, and Resulted in Tumor Infiltration and Cell Killing in Patients with Solid Tumors
- Abstract Number: 285
- Presentation Date & Time: Friday, Nov. 8, 2024, 12:15-1:45 p.m. and 5:25-6:55 p.m.
Multiomic profiling of LYL119: A Reprogrammed ROR1 CAR T Product Generates T cells with Reduced Exhaustion and Enhanced Memory Characteristics Associated with Increased AP-1 and Reduced NR4A Bindings
- Abstract Number: 283
- Presentation Date & Time: Friday, Nov. 8, 2024, 12:15-1:45 p.m. and 5:25-6:55 p.m.
Utilizing Stim-R™ Technology to Reduce Irradiated Feeder Cells in the Tumor Infiltrating Lymphocyte Culture Process
- Abstract Number: 440
- Presentation Date & Time: Saturday Nov. 9, 2024, 12:00-1:30 p.m. and 7-8:30 p.m.
About Lyell
Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies, including three product candidates in or entering Phase 1 clinical development for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel anti-exhaustion technology designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. Lyell applies its proprietary ex vivo genetic and epigenetic reprogramming technology to address these barriers to develop new medicines with improved durable clinical outcomes. Lyell is based in South San Francisco, California with facilities in Seattle and Bothell, Washington. To learn more, please visit www.lyell.com.
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell’s anticipated progress, business plans, business strategy and clinical trials; Lyell’s advancement of its pipeline and its research, development and clinical capabilities; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; the advancement of Lyell’s technology platform; and other statements that are not historical fact. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: the effects of macroeconomic conditions, including any geopolitical instability and actual or perceived changes in interest rates and economic inflation; Lyell’s ability to submit planned INDs or initiate or progress clinical trials on the anticipated timelines, if at all; Lyell’s limited experience as a company in enrolling and conducting clinical trials, and lack of experience in completing clinical trials; Lyell’s ability to manufacture and supply its product candidates for its clinical trials; the nonclinical profiles of Lyell’s product candidates not translating in clinical trials; the potential for results from clinical trials to differ from nonclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with Lyell’s product candidates; the significant uncertainty associated with Lyell’s product candidates ever receiving any regulatory approvals; Lyell’s ability to obtain, maintain or protect intellectual property rights related to its product candidates; implementation of Lyell’s strategic plans for its business and product candidates; the sufficiency of Lyell’s capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading “Risk Factors” in Lyell’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (SEC) on February 28, 2024, and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 7, 2024. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.
Contact:
Ellen Rose
Senior Vice President, Communications and Investor Relations
erose@lyell.com
FAQ
What is Lyell Immunopharma presenting at the 2024 SITC Annual Meeting?
What are the key findings from Lyell's LYL797 Phase 1 clinical trial?
What is the significance of Lyell's LYL119 product?